Literature DB >> 8189030

Malignancy-related ascites and ascitic fluid "humoral tests of malignancy".

B A Runyon.   

Abstract

A large number of ascitic fluid tests, e.g., fibronectin and cholesterol, have been proposed as helpful in detecting malignancy as the cause of ascites. Unfortunately, these "humoral tests of malignancy" are nonspecific. Although the ascitic fluid concentrations of these proteins or protein-bound substances tend to be quite high in patients with peritoneal carcinomatosis and low in the setting of cirrhotic ascites, the problem is that patients with tuberculous peritonitis, cardiac ascites, pancreatitis ascites, etc. usually have values in the malignancy range, i.e., false-positive results. This can lead to an extensive search for a nonexistent tumor, with confusion and anxiety for patient and physician. The cytology is the single best test to order when peritoneal carcinomatosis is suspected; its sensitivity approaches 100%. However, peritoneal carcinomatosis is only one of several mechanisms by which tumors can cause ascites. No one test can be expected to detect tumors as the cause of these diverse mechanisms of ascites formation. The serum-ascites albumin gradient is a helpful test in classifying ascitic fluid specimens into portal-hypertension-related and non-portal-hypertension-related categories. An elevated serum alpha-fetoprotein test can be useful in raising suspicion of hepatocellular carcinoma. Careful analysis of ascitic fluid, without measurement of "humoral tests of malignancy," combined with information obtained from the history and physical examination, usually lead to an accurate diagnosis of the cause of ascites.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8189030     DOI: 10.1097/00004836-199403000-00002

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

1.  Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites.

Authors:  Hong Zhang; Feng Li; Qun Wei; Yu-Fei Zhu
Journal:  Med Oncol       Date:  2010-11-02       Impact factor: 3.064

2.  Hepatobiliary quiz-6 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-06

3.  Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology.

Authors:  M Gulyás; A D Kaposi; G Elek; L G Szollár; A Hjerpe
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

4.  The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.

Authors:  Minkyu Jung; Hei-Cheul Jeung; Sung Sook Lee; Jun Yong Park; Soojung Hong; Soo Hyeon Lee; Sung Hoon Noh; Hyun Cheol Chung; Sun Young Rha
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-23       Impact factor: 4.553

5.  How valuable is ascitic cytology in the detection and management of malignancy?

Authors:  R O S Karoo; T D R Lloyd; G Garcea; H D Redway; G S R Robertson
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 6.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

7.  Toward a Reasoned Classification of Diseases Using Physico-Chemical Based Phenotypes.

Authors:  Laurent Schwartz; Olivier Lafitte; Jorgelindo da Veiga Moreira
Journal:  Front Physiol       Date:  2018-02-28       Impact factor: 4.566

8.  The Incidence of Free Peritoneal Tumor Cells before and after Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer.

Authors:  Rune B Strandby; Lars B Svendsen; Rikard Ambrus; Andreas A Rostved; Jane P Hasselby; Michael P Achiam
Journal:  J Cytol       Date:  2019-12-23       Impact factor: 1.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.